Lantheus

Company LNTH

Last mentioned: Feb 26, 2026

Stories mentioning Lantheus 2

pharma Neutral

Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.

12 sources
pharma Neutral

Natera and Lantheus Earnings: Precision Diagnostics and Radiopharma in Focus

As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.

4 sources